Cision PR Newswire

OncoC4 Announces NMPA Acceptance of Two IND Applications for Cesalatamig Combination Studies with ADCs and Pan-RAS Inhibitors

— New Studies Expand Cesalatamig into Biomarker-driven Precision Immuno-oncology Strategies — Cesalatamig is Also Being Evaluated in Ongoing Phase 2 Studies in the...

Julia Gillard joins Hakluyt’s International Advisory Board

LONDON, Oct. 19, 2026 /PRNewswire/ -- Hakluyt, the global strategic advisory firm for businesses...

2026 Canton Fair Design Award Winners Showcase China’s Innovation Strength

GUANGZHOU, China, Oct. 19, 2026 /PRNewswire/ -- As the 140th Canton Fair opens, the winners...